Aclidinium for Chronic Obstructive Pulmonary Disease
Author Information
Author(s): Paul W. Jones, Stephen I. Rennard, Alvar Agusti, Pascal Chanez, Helgo Magnussen, Leonardo Fabbri, James F. Donohue, Eric D. Bateman, Nick J. Gross, Rosa Lamarca, Cynthia Caracta, Esther Garcia Gil
Primary Institution: St George's, University of London
Hypothesis
The long-term efficacy and safety of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (COPD) were investigated.
Conclusion
Aclidinium is effective and well tolerated in patients with moderate to severe COPD.
Supporting Evidence
- Aclidinium improved trough FEV1 versus placebo in both studies.
- More patients had a significant improvement in health status with aclidinium.
- The time to first exacerbation was significantly delayed by aclidinium in one of the studies.
- Adverse events were minor in both studies.
Takeaway
Aclidinium helps people with breathing problems feel better and breathe easier.
Methodology
Two double-blind, 52-week studies were conducted where patients were randomized to receive aclidinium or placebo once daily.
Potential Biases
Potential bias due to the variability in individual patient responses and the use of concomitant medications.
Limitations
The studies were not powered for exacerbations and did not require a history of exacerbations for inclusion.
Participant Demographics
Patients aged ≥40 years, current or previous smokers with a history of COPD.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI 0.55 to 0.92
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website